Healthcare Representative Faints During Oval Office Announcement on Weight Loss Drugs
On Thursday, a healthcare executive from Novo Nordisk, Gordon Findlay, fainted at the Oval Office during an event focused on weight loss medications. The event was briefly halted as medical staff responded to the incident.
"During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted," said White House Press Secretary Karoline Leavitt. "The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly."
The event featured President Donald Trump and Dr. Mehmet Oz, who paused the proceedings to assist Findlay. After the brief interruption, the press was escorted out while medical attention was given.
The announcement centered on a deal between the U.S. government, Eli Lilly, and Novo Nordisk, aiming to offer obesity drugs to Americans for approximately $150 per monthly supply. President Trump revealed the agreement as part of broader efforts to lower healthcare costs.
According to White House Deputy Press Secretary Kush Desai, the press conference resumed at 1:29 p.m. following Findlay’s recovery and stabilization by the medical team.
Author’s Summary
Novo Nordisk executive Gordon Findlay collapsed during President Trump’s Oval Office health event, briefly interrupting a major weight loss drug announcement later resumed without further incident.